SND1 Antibody

1. SND1 may act as a potential biomarker of the therapeutic strategies utilizing COX2 inhibitors. PMID: 30365124
2. SND1 physically associated with and recruited the histone acetylase GCN5 to the promoter regions of Smad2/3/4, and consequently enhanced the gene transcriptional activation of Smad2/3/4, which are essential downstream regulators in the TGFbeta1 pathway. PMID: 28263968
3. Our work establishes an oncogenic role for SND1 in promoting tumor-initiating cell formation in hepatocellular carcinoma PMID: 28428278
4. Findings indicate the potential values of microRNA miR-320a, staphylococcal nuclease domain-containing 1 (SND1) and beta-catenin as prognostic biomarkers and therapeutic candidates for malignant gliomas. PMID: 28160566
5. These results highlight SND1 as a potential regulator of cellular cholesterol distribution and homeostasis in hepatoma cells, and support the rationale for the therapeutic use of molecules that influence cholesterol management when SND1 is overexpressed. PMID: 27238764
6. SND1 is a determinant downstream effector of TNFalpha that contributes to support glycerophospholipid homeostasis in human hepatocellular carcinoma during inflammation. PMID: 26323317
7. it could be concluded that miR-361-5p functions as a tumor-suppressive miRNA through directly binding to SND1 PMID: 25965817
8. we identified a new SND1-BRAF fusion that appeared to be present in a subpopulation of tumor cells. PMID: 25985019
9. Study is the first to show a novel regulatory role of SND1, a direct target of miR-184, in glioma progression, suggesting that the miR-184/SND1 axis may be a useful diagnostic and therapeutic tool for malignant glioma. PMID: 25216670
10. SND1 promoted expression of the E3 ubiquitin ligase Smurf1, leading to RhoA ubiquitination and degradation. PMID: 25596283
11. we describe the crucial role of SND1 in cancer development and progression, and highlight SND1 as a potential target for therapeutic intervention. PMID: 25405367
12. Single nucleotide polymorphism in SND1 gene is associated with osteosarcoma susceptibility. PMID: 25663449
13. Tudor-SN is a potential substrate of G1/S phase Cyclin-Dependent Kinases, and promotes cell cycle progression by facilitating E2F-1-mediated gene transcription. PMID: 25627688
14. Promoter activity of the cell growth- and RNA-protection associated SND1 gene is up-regulated by ER stress in human hepatoma cells PMID: 25494629
15. Tudor-SN regulates the aggregation dynamics of poly(A(+) mRNA-containing stress granules and selectively stabilizes the stress granules-associated mRNA during cellular stress. PMID: 25559396
16. The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells. PMID: 23995791
17. MTDH supports the survival of mammary epithelial cells under oncogenic/stress conditions by interacting with and stabilizing SND1. PMID: 24981741
18. Tudor-SN plays an important role in the assembly of AGTR1-3'UTR granules. Moreover, endogenous Tudor-SN knockdown can decrease the recovery kinetics of AGTR1-3'UTR granules. PMID: 24815690
19. High Tudor-SN expression is associated with breast cancer. PMID: 24155205
20. High SND1 expression is associated with hepatocellular carcinoma. PMID: 23878061
21. SND1 silencing resolved this block in processing and induced an increase in mature miRs. Together, SND1 might be the missing link between hypoxia and the differential regulation of miRNA processing PMID: 23770094
22. a transcriptional network associated to the key transcription factors NF-kappaB, Sp1 and NF-Y that operates in the control of the SND1 gene expression PMID: 23160072
23. The increased expression of MTDH and/or SND1 is closely related to carcinogenesis, progression, and prognosis of colon cancer. PMID: 23065261
24. SND1 promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor kappaB and miR-221 PMID: 22396537
25. this novel B-Raf fusion protein (SND-1 was identified as the B-Raf fusion partner) presents a novel target with potential clinical implications in the treatment of patients resistant to c-Met inhibitors. PMID: 21936566
26. SND1 as a novel MTDH-interacting protein and shown that it is a functionally and clinically significant mediator of metastasis. PMID: 21478147
27. These results provide evidence that p100 interacts with the 3' UTR of dengue virus and is required for normal dengue virus replication. PMID: 21148275
28. The coacitivator p100 protein can interact with STAT6 through its SN domain both in vivo and in vitro, resulting in enhancement of STAT6-mediated gene transcriptional acitivation. PMID: 20225206
29. These findings identify p100 as a novel coactivator for STAT6 and suggest that p100 functions as a bridging factor between STAT6 and the basal transcription machinery. PMID: 12234934
30. p100 has an important role in the assembly of STAT6 transcriptosome, and that p100 stimulates IL-4-dependent transcription by mediating interaction between STAT6 and CBP and recruiting chromatin modifying activities to STAT6-responsive promoters PMID: 15695802
31. The p100 protein is a novel dual function regulator of gene expression that participates via distinct domains in both transcription and splicing. PMID: 17576664
32. The tudor and SN (TSN) domain of p100 interacts with U small nuclear ribonucleoprotein (snRNP) complexes, suggesting a role for p100 in the processing of precursor messenger RNA. PMID: 17632523
33. Data showed remarkable up-regulation of SND1 mRNA in human colon cancer tissues, even in early-stage lesions, and also in colon cancer cell lines. PMID: 17909068
34. Tudor-SN requires tandem repeats of SN domains for its RNA binding and cleavage activity. PMID: 18453631
35. SND! represents promising prostate cancer biomarker and therapeutic target. PMID: 19435788

Show More

Hide All

HGNC: 30646

OMIM: 602181

KEGG: hsa:27044

STRING: 9606.ENSP00000346762

UniGene: Hs.122523